343 related articles for article (PubMed ID: 32110053)
1. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
2. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas.
Liu Z; Yao W; Zhao Y; Liu O; Zhang P; Ge H
Cancer Manag Res; 2021; 13():1009-1016. PubMed ID: 33574700
[TBL] [Abstract][Full Text] [Related]
4. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
Sun X; Xu J; Xie L; Guo W
Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
Cai M; Zhu J; Zhou G
Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study.
Wu J; Li C; Liu B; Liu Q; Liu D; Wang Z; Wang X; Jia W; Tian X; Hao C
Ann Transl Med; 2023 Mar; 11(5):212. PubMed ID: 37007540
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
Front Oncol; 2021; 11():683502. PubMed ID: 34692475
[TBL] [Abstract][Full Text] [Related]
11. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer.
Huang JY; Xie XF; Chen XL; Zhang QY; Chen LP; Bai X; Lan XF; Song L; Guo JF; Du CW
Front Oncol; 2023; 13():1122294. PubMed ID: 37124484
[TBL] [Abstract][Full Text] [Related]
12. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
16. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.
Zou H; Xia L; Jin G; Wu H; Qian W; Jia D; Xu H; Li T
Cancer Manag Res; 2022; 14():1703-1711. PubMed ID: 35585940
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
20. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]